DDInter973 DDInter875
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Irinotecan {u} (Compound) treats {v} (Disease) hematologic cancer
Irinotecan {u} (Compound) binds {v} (Gene) ABCC1
Irinotecan {u} (Compound) upregulates {v} (Gene) PHLDA3
Irinotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Irinotecan {u} (Compound) downregulates {v} (Gene) PCMT1
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Irinotecan (Compound) treats hematologic cancer (Disease)
Irinotecan (Compound) binds ABCC1 (Gene)
Irinotecan (Compound) upregulates PHLDA3 (Gene)
Irinotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Irinotecan (Compound) downregulates PCMT1 (Gene)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Verapamil